Abstract |
Thirteen patients with stage III or IV carcinoma of the prostate were treated with 2,6-cis-Diphenylhexamethylcyclotetrasiloxane ( Cisobitan, a new organosilicon compound. The drug proved to be a strong antiandrogen and exerted all the known effects of estrogens, including feminization and cardiovascular complications. It is therefore doubtful whether Cisobitan will be a reasonable alternative to estrogens in the treatment of patients with advanced prostatic cancer.
|
Authors | T Krarup, F Rasmussen, P A Gammelgaard |
Journal | Scandinavian journal of urology and nephrology
(Scand J Urol Nephrol)
Vol. 12
Issue 1
Pg. 11-5
( 1978)
ISSN: 0036-5599 [Print] England |
PMID | 345431
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Androgen Antagonists
- Silicones
- Siloxanes
|
Topics |
- Aged
- Androgen Antagonists
(administration & dosage, adverse effects, therapeutic use)
- Clinical Trials as Topic
- Drug Evaluation
- Humans
- Male
- Prostatic Neoplasms
(drug therapy)
- Silicones
(therapeutic use)
- Siloxanes
(administration & dosage, adverse effects, therapeutic use)
|